Abstract:Pt(IV) anticancer compounds have been developed for several decades to overcome the drawbacks of their Pt(II) congeners, and the reduction of Pt(IV) to Pt(II) has been commonly regarded as a necessary step in the activation of Pt(IV) compounds prior to targeting DNA. However, blockage of glutathione (GSH) biosynthesis resulted in a slight effect on the cytotoxicity of oxoplatin in yeast Saccharomyces cerevisiae strains, urging us to reconsider the mechanism of actions for the "inert" Pt(IV) complexes. Using X-ray absorption near-edge spectroscopy (XANES), our data demonstrated that Pt(IV) complex oxoplatin could bind to DNA in a tetravalent state. Both alkaline denaturing agarose electrophoresis and thermal denaturation-renaturation assay revealed that oxoplatin could rapidly produce stable interstrand crosslinks (ICLs), which can further translate into a fast cell-killing process in cancer cells. Using quantitative real-time PCR and immunofluorescence analysis, we also proved that Pt(IV) complex oxoplatin could induce a quick intracellular response of the FA/BRCA pathway in cancer cells that involves the DNA interstrand crosslinking repair system, and this quick response to ICLs was independent with the intracellular GSH levels. Cell cycle analysis showed that short incubation with oxoplatin can induce a strong S phase arrest in HeLa cells, indicating that the rapid interstrand crosslinks produced by oxoplatin might stall the replication fork, result in the double-strand breaks, and eventually induce cell death. Our results implied that, besides the reduction mechanism to release the Pt(II) congeners, direct and rapid interstrand cross-linking with DNA by Pt(IV) compounds might be a unique mechanism for Pt(IV) compounds, which may provide new insight for the development of next-generation platinum-based drugs.

Identification and Characterization of DNA-Oxaliplatin Adducts through α-hemolysin Nanopores

Rapid DNA interstrand cross-linking of Pt(IV) compound

Study on the Interactions Between Anti-Cancer Drug Oxaliplatin and DNA

Proteomic Analysis of Cisplatin- and Oxaliplatin-Induced Phosphorylation in Proteins Bound to Pt-DNA Adducts.

Detection and Characterization of Single Cisplatin Adducts on DNA by Nanopore Sequencing

Structural study on the interactions of oxaliplatin and linear DNA.

Nanopore Sequencing Accurately Identifies the Cisplatin Adduct on DNA.

Structural characterization and DNA interactions of new cytotoxic transplatin analogues containing one planar and one nonplanar heterocyclic amine ligand

Clickable Cisplatin Derivatives as Versatile Tools to Probe the DNA Damage Response to Chemotherapy

Study on the interactions between anti-cancer drug oxaliplatin and DNA by atomic force microscopy

Nucleic Acid‐based Electrochemical Sensors Facilitate the Study of DNA Binding by Platinum (II)‐based Antineoplastics

Interaction Between DNA and Oxaliplatin in Aqueous Solution Studied Using THz-TDS

Sensitive Marker of the Cisplatin-DNA Interaction: X-Ray Photoelectron Spectroscopy of CL.

Synthesis of mesoporous silica nanoparticle-oxaliplatin conjugates for improved anticancer drug delivery

DNA-mediated Inhibition of Peroxidase-Like Activities on Platinum Nanoparticles for Simple and Rapid Colorimetric Detection of Nucleic Acids.

Nanopore Single-Molecule Analysis of Dna Doxorubicin Interactions

Discovery Of Cisplatin Binding To Thymine And Cytosine On A Single-Stranded Oligodeoxynucleotide By High Resolution Ft-Icr Mass Spectrometry

Effective monitoring of Platinum-DNA adducts formation under simulated physiological conditions by CE-ICP-MS/MS

Synthesis and DNA Interactions Study of Novel Fluorinated Pyridinium Platinum (IV) Complexes with Tumor Targeting Activity

Unraveling and Overcoming Platinum Drug‐Resistant Cancer Tumors with DNA Nanostructures

The role of carrier ligands of platinum(II) anticancer complexes in the protein recognition of Pt–DNA adducts